Video
Dr. Wetzler on Autologous Transplantation in Ph+ALL
Author(s):
Meir Wetzler, MD, explains the CALGB 10001 study analyzing autologous and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, explains the CALGB 10001 study analyzing autologous and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
The authors of the study hypothesized that an imatinib and sequential chemotherapy regimen would allow for the collection of a patient’s normal hematopoietic stem cells not contaminated by residual BCR/ABL+ lymphoblasts and reduce the likelihood of relapse after an autologous transplantation.
The study found that autologous transplantation is a safe and effective alternative to allogeneic transplantation for patients with Ph+ALL.
